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AFP

:   alpha‐fetoprotein

ALT

:   alanine transaminase

ARC

:   arthrogryposis‐renal dysfunction‐cholestasis

AST

:   aspartate aminotransferase

BRIC

:   benign recurrent intrahepatic cholestasis

BSEP

:   bile salt export pump

CK

:   cytokeratin

DB

:   direct bilirubin

EDTA

:   ethylenediaminetetraacetic acid

FXR

:   nuclear farnesoid X receptor

gDNA

:   genomic DNA

GGT

:   gamma‐glutamyltransferase

H&E

:   hematoxylin and eosin

IHC

:   immunohistochemical

LT

:   liver transplantation

MVID

:   microvillus inclusion disease

MYO5B

:   myosin VB

P

:   patients

PFIC

:   progressive familial intrahepatic cholestasis

RAB11A

:   RAS‐related GTP‐binding protein 11A

TB

:   total bilirubin

TBA

:   total bile acids

TJP2

:   tight junction protein 2

TNC

:   transient neonatal cholestasis

UDCA

:   ursodeoxycholic acid

UPLC−ESI/MRM‐MS

:   ultrahigh performance liquid chromatography--electrospray ionization/multiple reaction monitoring mass spectrometry

Hereditary cholestasis with conjugated hyperbilirubinemia in children presents as a range of disorders, from transient neonatal cholestasis (TNC) through benign recurrent intrahepatic cholestasis (BRIC) to progressive familial intrahepatic cholestasis (PFIC).[1](#hep29020-bib-0001){ref-type="ref"}, [2](#hep29020-bib-0002){ref-type="ref"}, [3](#hep29020-bib-0003){ref-type="ref"}, [4](#hep29020-bib-0004){ref-type="ref"} Of children with such cholestasis and low or normal serum gamma‐glutamyltransferase (GGT) activity (GGT \<100 IU/L; "low‐GGT cholestasis"),[1](#hep29020-bib-0001){ref-type="ref"} two thirds carry either *ATP8B1* [5](#hep29020-bib-0005){ref-type="ref"}, [6](#hep29020-bib-0006){ref-type="ref"} or *ABCB11* mutations[7](#hep29020-bib-0007){ref-type="ref"}, [8](#hep29020-bib-0008){ref-type="ref"}, [9](#hep29020-bib-0009){ref-type="ref"}; the remaining instances of childhood cholestasis with conjugated hyperbilirubinemia and low GGT can sometimes be attributed to mutations in *TJP2*,[10](#hep29020-bib-0010){ref-type="ref"} which encodes tight junction protein 2 (TJP2); in genes involved in bile acid synthesis, including *HSD3B7*,[11](#hep29020-bib-0011){ref-type="ref"} *AKR1D1*,[12](#hep29020-bib-0012){ref-type="ref"} *CYP7B1*,[13](#hep29020-bib-0013){ref-type="ref"} *AMACR*,[14](#hep29020-bib-0014){ref-type="ref"} and *CYP27A1* [15](#hep29020-bib-0015){ref-type="ref"}; in *VPS33B* and *VIPAS39*, which cause arthrogryposis‐renal dysfunction‐cholestasis (ARC) syndrome[16](#hep29020-bib-0016){ref-type="ref"}, [17](#hep29020-bib-0017){ref-type="ref"}; and in *NR1H4*, encoding the nuclear farnesoid X receptor (FXR)[18](#hep29020-bib-0018){ref-type="ref"} (see [Supporting Table S1](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo)). However, approximately one fifth of such patients remain without an identified genetic defect,[10](#hep29020-bib-0010){ref-type="ref"} suggesting that mutations at additional loci are responsible for childhood low‐GGT cholestasis. Myosin VB (MYO5B), associated with plasma membrane recycling and transcytosis,[19](#hep29020-bib-0019){ref-type="ref"}, [20](#hep29020-bib-0020){ref-type="ref"} is essential to polarization of hepatocytes, enterocytes, and respiratory epithelial cells through protein‐protein interactions with RAS‐related GTP‐binding protein 11A (RAB11A), RAB8A, and cystic fibrosis transmembrane conductance regulator, respectively.[21](#hep29020-bib-0021){ref-type="ref"}, [22](#hep29020-bib-0022){ref-type="ref"} The interaction of MYO5B with RAB11A also appears essential for targeting bile salt export pump (BSEP) to the canalicular membrane [23](#hep29020-bib-0023){ref-type="ref"}.

Functional deficiency in MYO5B, or absolute deficiency of MYO5B, results in aberrant cell polarity and is the major cause of microvillus inclusion disease (MVID; MIM 251850), an autosomal‐recessive disorder causing persistent watery diarrhea manifest in infancy that requires parenteral alimentation and even intestinal transplantation.[24](#hep29020-bib-0024){ref-type="ref"}, [25](#hep29020-bib-0025){ref-type="ref"}, [26](#hep29020-bib-0026){ref-type="ref"}, [27](#hep29020-bib-0027){ref-type="ref"} Cholestasis with normal‐range GGT and intractable pruritus has been reported as an atypical symptom or as a side effect of parenteral nutrition in some MVID patients before or after intestinal transplantation[28](#hep29020-bib-0028){ref-type="ref"}, [29](#hep29020-bib-0029){ref-type="ref"}, [30](#hep29020-bib-0030){ref-type="ref"} and is associated with altered targeting of BSEP to the canalicular membranes of hepatocytes.[31](#hep29020-bib-0031){ref-type="ref"}

To identify the underlying causes of cholestasis of undetermined etiology in patients with normal serum GGT and without demonstrable mutations in known candidate genes, we performed whole‐exome sequencing (WES) and targeted sequencing. In a subset of these patients, we identified biallelic mutations in *MYO5B*, which encodes MYO5B. Through immunostaining and bile acid profiling, we demonstrated that these patients had impaired MYO5B and BSEP expression as well as plasma bile acid profiles similar to those observed in severe primary BSEP/ABCB11 disease (PFIC2). Our work implicates *MYO5B* mutation as capable of reproducing the full clinical spectrum of isolated low‐GGT cholestasis.

Subjects and Methods {#hep29020-sec-0002}
====================

SUBJECTS {#hep29020-sec-0003}
--------

Study subjects were Han Chinese enrolled from 2011 to 2016, with informed consent, under a clinical‐diagnosis protocol approved by Children\'s Hospital and Jinshan Hospital of Fudan University (Shanghai, China) and according to the ethical guidelines of the 1975 Declaration of Helsinki. The following enrollment criteria were used: elevated serum total bilirubin (TB) and direct bilirubin (DB); GGT \<100 IU/L; failure to ascertain an etiology of disease through testing listed in [Supporting Table S2](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo) [32](#hep29020-bib-0032){ref-type="ref"}, [33](#hep29020-bib-0033){ref-type="ref"}; and parental DNA available. All patients were analyzed either by WES or targeted sequencing. The first cohort included 24 patients enrolled from 2011 to 2014. After the identification of 5 cases with *MYO5B* defects in the first cohort (patients \[P\] 1‐5), we retrospectively reviewed undiagnosed cholestasis patients admitted from 2011 to 2015. From them, we selected 7 more patients with available liver biopsy specimens as a second cohort. Two patients with *MYO5B* defects were identified in this cohort (P6 and P7) by immunohistochemical (IHC) and DNA sequencing analyses (detailed in Results, Figs. [1](#hep29020-fig-0001){ref-type="fig"}, [2](#hep29020-fig-0002){ref-type="fig"}, [3](#hep29020-fig-0003){ref-type="fig"}). Three sporadic instances of *MYO5B* defects also were identified. Patients 8 and 9 were found using a new genetic screening panel that included *MYO5B*. Patient 10 was found by WES as part of clinical investigation of recurring cholestasis. None of the patients\' families were related to any other patients\' family.

![Histological findings in *MYO5B* mutant patients (original magnification, all images, ×400). On H&E staining, hepatocellular and canalicular cholestasis, lobular disarray, mild inflammation, and portal‐tract fibrosis were apparent in all specimens. Giant‐cell formation was observed in all patients, with ballooning degeneration of hepatocytes in P4 and P7. CK7 and CK19 immunostaining revealed ductular reaction in all patients but P6, as well as weak heterotopic CK7 expression in some hepatocytes.](HEP-65-1655-g001){#hep29020-fig-0001}

![MYO5B expression in *MYO5B* mutant patients (original magnification, all principal images, ×200; insets, ×400). (A) Choledochal cyst control without cholestasis; (B) incidentally resected normal liver control (adjoining excised tumor); (C) biliary atresia control with cholestasis. MYO5B Patients P3‐P5, P6, and P7: Much coarsely granular pigment was observed in every patient specimen (Fig. [3](#hep29020-fig-0003){ref-type="fig"}, P3‐P5, P6, and P7), whereas fewer and finer MYO5B‐positive granular deposits were observed in the control individuals, mainly distributed around portal areas (Fig. [3](#hep29020-fig-0003){ref-type="fig"} A,B). The size and number of positive granules in the biliary atresia patient (Fig. [3](#hep29020-fig-0003){ref-type="fig"}C) were intermediate between those of the patient group and the control group; the granules in this patient were periportal.](HEP-65-1655-g002){#hep29020-fig-0002}

![BSEP staining in *MYO5B* mutant patients (original magnification, all principal images, ×400; insets, 900×). (A) Choledochal cyst control without cholestasis; (B) incidentally resected normal liver control (adjoining excised tumor); (C) biliary atresia control with cholestasis; (D) confirmed PFIC2 patient with biallelic *ABCB11* mutations (p.I498T / p.R415X); (E) discarded normal liver control (healthy liver donor). MYO5B patients P3‐P5, P6, and P7: Compared to the control A and B, less expression of BSEP was observed in P3, P4, P6, and P7 (Fig. [3](#hep29020-fig-0003){ref-type="fig"}, P3‐P4, P6, and P7), whereas expression was blurred at canaliculi and adjacent cytoplasm in P5 (Fig. [3](#hep29020-fig-0003){ref-type="fig"}, P5). Black arrows indicate abnormalities in P5 and P7 (insets).](HEP-65-1655-g003){#hep29020-fig-0003}

Twenty‐six patients (all Han Chinese) with unexplained high‐GGT cholestasis or other forms of liver disease from the same geographical regions were listed as "other‐liver‐disease controls," and 338 patients with neurological disorders or unknown genetic disorders without liver disease were used as "nonliver controls." All controls were analyzed by WES.

GENETIC ANALYSES {#hep29020-sec-0004}
----------------

Genomic DNA (gDNA) was extracted from ethylenediaminetetraacetic acid (EDTA)‐treated peripheral blood cells (QIAamp DNA Blood Mini Kit, Catalog No. 51106; Qiagen, Germany) of the enrolled patients and their available family members. WES was performed using patient gDNA with a SureSelectXT Reagent kit (Catalog No. G9611A; Agilent, Santa Clara, CA, USA), SureSelectXT Human All Exon V5 (Catalog No.5190‐6208; Agilent), TruSeq PE Cluster Kit v3‐cBot‐HS (Catalog No. PE‐401‐3001; Illumina, San Diego, CA, USA), and HiSeq SBS Kit V4 (Catalog No. FC‐401‐4003; Illumina). Quantification was performed with an Agilent 2100 Bioanalyzer (Catalog No.G2938A; Agilent), and multiplexed sequencing was done on HiSeq 2500 sequencers with 2 × 150 paired‐end modules (Illumina). Total sequencing depth was 100×. WES and annotation were done by Genesky Biotechnologies (Shanghai, China). [Supporting Fig. S1](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo) shows the filtering procedures for the WES data. Online resources GeneCards, Orphanet, JuniorDoc online database, ClinVar, OMIM, and PubMed were used to search for genes known to be pathogenically mutated in liver disease and genes expressed in or functionally related to liver. HGMD, dbSNP, Exome Variant Server (ESP6500), 1000 Genomes, and ExAC Browser were applied to filter common variants. Polyphen2, SIFT, and MutationTaster[34](#hep29020-bib-0034){ref-type="ref"} were used to predict the pathogenicity of candidate variants. In addition, an internal database (data not shown) was used to filter common variants or common sequencing errors. We also included a candidate list containing reported hereditary disorders with liver presentations or associated with liver metabolism (data not shown). Predicted pathogenic variants of suspect genes were verified through PCR (2\*Master Mix, Catalog No. KT201; Tiangen, Shanghai, China) followed by Sanger sequencing in the patient and his or her family members. Low‐coverage (coverage lower than 5) exons in candidate genes were also subjected to Sanger sequencing. Primers and PCR conditions are available on request.

HISTOLOGICAL AND IHC STUDIES {#hep29020-sec-0005}
----------------------------

Specimens of liver were fixed in 4% acetic formalin, embedded in paraffin, cut into 4‐micron sections, stained with hematoxylin and eosin (H&E), and immunostained with antibodies against cytokeratin (CK) 7 (monoclonal mouse anti‐human, OV‐TL12/30, ready to use; Agilent, Santa Clara, CA, USA) and CK19 (monoclonal mouse anti‐human, RCK108, ready to use; Agilent). Immunostaining with anti‐MYO5B antibodies (N‐term human MYO5B, Ab190096; Abcam, Cambridge, UK) and anti‐BSEP monoclonal antibody (mouse anti‐human, F‐6, sc‐74500; Santa Cruz Biotechnology, Dallas, TX, USA) were also performed. Specimens from patients and normal controls were stained together on the same slide when performing immunostaining.

For a diagnosis‐blinded review of BSEP (ABCB11) immunostaining, unstained slides were sent to B.S. Slides were subjected to heat‐induced antigen retrieval (CC1; Ventana Medical Systems, Tucson, AZ) and immunostained with rabbit polyclonal anti‐BSEP antibody (HPA 19035, 1:2,000 dilution; Sigma‐Aldrich, Taufkirchen, Germany), with diaminobenzidine as chromogen and hematoxylin as counterstain, using a Benchmark Ultra Immunostainer (Ventana). Normal human liver was used as a positive control. Slides were reviewed by two independent pathologists (A.S.K. and B.S.) with no knowledge of associated clinical or genetic information.

ANALYSIS OF BILE ACIDS IN PLASMA {#hep29020-sec-0006}
--------------------------------

Plasma samples were collected from EDTA‐treated peripheral blood by centrifugation. Analysis of bile acids in plasma by ultrahigh performance liquid chromatography--electrospray ionization/multiple reaction monitoring mass spectrometry (UPLC−ESI/MRM‐MS) with negative ion detection was performed at the University of Victoria--Genome British Columbia Proteomics Centre (Victoria, BC, Canada), using described sample preparation and quantitation procedures.[35](#hep29020-bib-0035){ref-type="ref"}

GENOTYPE‐PHENOTYPE CORRELATION IN *MYO5B*‐MUTATED PATIENTS {#hep29020-sec-0007}
----------------------------------------------------------

To explore the phenotype‐genotype relationship, patients with genetically confirmed *MYO5B* disease identified in this study, and those in published reports,[24](#hep29020-bib-0024){ref-type="ref"}, [25](#hep29020-bib-0025){ref-type="ref"}, [27](#hep29020-bib-0027){ref-type="ref"}, [29](#hep29020-bib-0029){ref-type="ref"}, [36](#hep29020-bib-0036){ref-type="ref"}, [37](#hep29020-bib-0037){ref-type="ref"}, [38](#hep29020-bib-0038){ref-type="ref"} were divided into isolated cholestasis or MVID subgroups. All mutations were categorized in two ways, severe versus nonsevere, and MYO5B‐RAB11A interaction domain‐related versus unrelated. Frameshift, nonsense, and classical splicing mutations were defined as severe mutations. Mutations located in the MYO5B‐RAB11A interaction domain, or mutations predicted to influence interactions at that domain,[39](#hep29020-bib-0039){ref-type="ref"} were termed MYO5B‐RAB11A domain‐related mutations. The proportions of patients with biallelic severe mutations, or with biallelic mutations related to MYO5B‐RAB11A interaction, were compared between the subgroups.

STATISTICAL ANALYSIS {#hep29020-sec-0008}
--------------------

Fisher\'s exact test was performed, using the software package STATA 10 (StataCorp LP, College Station, TX, USA) for mutation frequency analysis, to compare patients carrying biallelic *MYO5B* mutations in the first cohort with "other liver‐disease controls" and "nonliver disease controls." The same methods were used to explore the phenotype‐genotype relationship in genetically confirmed *MYO5B‐*mutated patients. To avoid dependence between samples, 1 patient from multipatient sibships was randomly selected for statistical analysis. Rank‐sum tests were performed using the software package SPSS 19 (IBM, Armonk, NY) to compare bile acid profiles of *MYO5B*‐mutated patients with those of PFIC2 patients and controls.

Results {#hep29020-sec-0009}
=======

BIALLELIC *MYO5B* MUTATIONS ARE ASSOCIATED WITH LOW‐GGT CHOLESTASIS WITHOUT RECURRENT DIARRHEA {#hep29020-sec-0010}
----------------------------------------------------------------------------------------------

We identified 15 *MYO5B* mutations, three known and 12 novel, in 10 cholestatic patients. Among these, two nonsense mutations (c.1021C\>T, p.Q341X; c.3046C\>T, p. R1016X) had been reported in MVID patients without cholestasis,[27](#hep29020-bib-0027){ref-type="ref"}, [36](#hep29020-bib-0036){ref-type="ref"} and one missense mutation (c.1604G\>A, p.S535N) has a reported frequency of 0.001 in East Asian populations in the ExAC database ([http://exac.broadinstitute.org/variant/18‐47480747‐C‐T](http://exac.broadinstitute.org/variant/18-47480747-C-T)), but is predicted to be disease causing (Table [1](#hep29020-tbl-0001){ref-type="table-wrap"}). SIFT and Polyphen2 and/or MutationTaster predicted that the novel mutations would result in loss of MYO5B function or cause disease (Table [1](#hep29020-tbl-0001){ref-type="table-wrap"}).

###### 

Mutations in *MYO5B* (NM_001080467) in Low‐GGT Cholestasis Patients in This Study[a](#hep29020-note-0002){ref-type="fn"}

  Patient                                     Mutation                                            Predicted Effects   MYO5B Domain   Zygosity       Origin              HGMD ID                                            Predicted Effect, MYO5B‐Rab11a Domain   SIFT          Polyphen
  ------------------------------------------- --------------------------------------------------- ------------------- -------------- -------------- ------------------- -------------------------------------------------- --------------------------------------- ------------- -------------------
  *Patients with biallelic mutation*                                                                                                                                                                                                                                             
  P1 and P2                                   c.3538‐1G\>A                                        Splicing            Coiled coil    Heterozygous   Father              ---                                                Abolish interaction                     N/A           N/A
                                              c.2414+5G\>T                                        Splicing            IQ             Heterozygous   Mother              ---                                                None                                    N/A           N/A
  P3                                          c.1201C\>T                                          p.R401C             Head           Heterozygous   Father              ---                                                None                                    Deleterious   Probably damaging
                                              c.1021C\>T                                          p.Q341X             Head           Heterozygous   Mother              CM108966[36](#hep29020-bib-0036){ref-type="ref"}   Abolish interaction                     N/A           N/A
  P4                                          c.3237G\>C                                          p.Q1079H            Coiled coil    Heterozygous   Father              ---                                                None                                    Deleterious   Possibly damaging
                                              c.1604G\>A                                          p.S535N             Head           Heterozygous   Mother              ---                                                Abolish interaction                     Tolerated     Possibly damaging
  P5                                          c.796T\>C                                           p.C266R             Head           Homozygous     Father and mother   ---                                                Abolish interaction                     Deleterious   Probably damaging
  P6[b](#hep29020-note-0003){ref-type="fn"}   c.1748G\>A                                          p.S583N             Head           Heterozygous   ND                  ---                                                Abolish interaction                     Deleterious   Probably Damaging
                                              c.2801T\>G                                          p.I934S             Coiled coil    Heterozygous   ND                  ---                                                Abolish interaction                     Deleterious   Possibly damaging
  P7[b](#hep29020-note-0003){ref-type="fn"}   c.2090_2090delG                                     p.R697Gfs\*74       Head           Heterozygous   ND                  ---                                                Abolish interaction                     N/A           N/A
                                              c.4852+11A\>G                                       Splicing            Tail           Heterozygous   ND                  ---                                                N/A                                     N/A           N/A
  P8 and P9                                   c.3046C\>T                                          p.R1016X            Coiled coil    Heterozygous   Mother              CM085576[27](#hep29020-bib-0027){ref-type="ref"}   Abolish interaction                     N/A           N/A
  P8 and P9                                   c.437C\>T                                           p.S158F             Head           Heterozygous   Father              ---                                                None                                    Deleterious   Possibly damaging
  P10                                         c.2470C\>T[b](#hep29020-note-0003){ref-type="fn"}   p.R824C             IQ             Homozygous     Father and mother   ---                                                None                                    Deleterious   Probably damaging
  *Patients with monoallelic mutation*                                                                                                                                                                                                                                           
  P11                                         c.2470C\>T[b](#hep29020-note-0003){ref-type="fn"}   p.R824C             IQ             Heterozygous   Mother              ---                                                None                                    Deleterious   Probably damaging
  P12                                         c.1136G\>C[b](#hep29020-note-0003){ref-type="fn"}   p.R379P             Head           Heterozygous   Father              ---                                                None                                    Deleterious   Possibly damaging

MutationTaster assessed all mutations as disease‐causing.

While this article was under review, two additional *MYO5B* mutations causing isolated cholestasis were reported.[38](#hep29020-bib-0038){ref-type="ref"} One is c.2470C\>T, p.R824C. The other is 1135C\>T, p.R379C, which changes the same codon as 1136G\>C, reported here.

Abbreviations: N/A, not applicable; IQ, Isoleucine‐glutamine (IQ) calmodulin‐binding consensus sequence; ND, not done.

In the first cohort of 24 patients, biallelic *MYO5B* mutations were detected in 5 patients (P1--P5; Table [1](#hep29020-tbl-0001){ref-type="table-wrap"}) from four unrelated families. No disease‐causing mutation that matched this inheritance mode was detected in other genes associated with cholestasis ([Supporting Table S3](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo)). In addition, monoallelic *MYO5B* mutations were detected in 2 patients (P11 and P12; Table [1](#hep29020-tbl-0001){ref-type="table-wrap"}). The frequency of *MYO5B* mutations is significantly higher in this group than in the "other‐liver‐disease controls" (5 of 24 vs. 0 of 26, Fisher\'s exact test; *P* = 0.02) and in the "nonliver controls" (one sample in this group contained two *MYO5B* variants and was treated as a compound heterozygote, though not confirmed as such because of unavailability of parental samples; 5 of 24 vs. 1 of 338, Fisher\'s exact test; *P* = 4.84 × 10^--6^), indicating a strong association between *MYO5B* mutation and low‐GGT cholestasis without diarrhea.

In the second cohort, two *MYO5B* mutations were found in 2 of the 3 patients sent for targeted sequencing because liver biopsy had found histopathologic features like those of *MYO5B* disease as established in the first cohort (Figs. [1](#hep29020-fig-0001){ref-type="fig"}, [2](#hep29020-fig-0002){ref-type="fig"}, [3](#hep29020-fig-0003){ref-type="fig"}). However, compound heterozygosity was not confirmed given that parental samples were not available. No *MYO5B* mutation was found in either the third patient who underwent targeted sequencing or the remaining 4 who underwent WES.

Two mutations in *MYO5B* were found in patient P8 after introduction of a new screening panel that included *MYO5B* (Table [1](#hep29020-tbl-0001){ref-type="table-wrap"}). Compound heterozygosity was confirmed by studies in her parents. Her younger brother, with icterus (P9), harbored the same mutations. Homozygous *MYO5B* mutation was discovered by WES in P10, who had recurrent bouts of cholestasis.

CLINICAL FEATURES OF CHOLESTATIC PATIENTS WITH *MYO5B* MUTATIONS {#hep29020-sec-0011}
----------------------------------------------------------------

All 10 patients with two *MYO5B* mutations were born at term, with normal weight, to healthy, unrelated parents. Pregnancy and parturition were unremarkable in all mothers. No patient suffered recurrent diarrhea or received parenteral alimentation. All presented with cholestasis and elevated DB, low GGT, mildly elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values, and elevated serum total bile acid (TBA) concentrations. Blood glucose, ammonia, and alpha‐fetoprotein (AFP) values were all within expected ranges. The rest of their examination results were unremarkable. The principal medications routinely administered were ursodeoxycholic acid (UDCA) and fat‐soluble vitamins; cholestyramine was added to alleviate unresolved pruritus and/or cholestasis. Other major clinical and biochemical details are shown in Table [2](#hep29020-tbl-0002){ref-type="table-wrap"}.

###### 

Clinical and Laboratory Attributes of MYO5B Disease Patients

  Patients                                                                                        P1                               P2                          P3                                           P4                                         P5                                        P6                                         P7                                         P8                                               P9                          P10
  ----------------------------------------------------------------------------------------------- -------------------------------- --------------------------- -------------------------------------------- ------------------------------------------ ----------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------------ --------------------------- ------------------------------------------------
  Sex                                                                                             M                                M                           F                                            M                                          M                                         M                                          M                                          F                                                M                           M
  Maternal ICP                                                                                    ---                              ---                         ---                                          ---                                        ---                                       ---                                        ---                                        ---                                              ---                         ---
  Maternal spontaneous abortion                                                                   0                                0                           1                                            2                                          1                                         0                                          0                                          0                                                0                           0
  Siblings                                                                                        One affected brother (P2)        One affected brother (P1)   One healthy brother                          None                                       None                                      One healthy brother                        None                                       One affected brother (P9)                        One affected sister (P8)    One healthy sister
  Presenting age                                                                                  8mo                              19mo                        1mo                                          2d                                         6mo                                       15d                                        3mo                                        7mo                                              1mo                         7mo
  Status at first assessment                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Age                                                                                             9mo                              18mo                        2mo                                          1mo                                        6mo                                       3mo                                        4mo                                        10.0y                                            6mo                         11mo
  Lithiasis                                                                                       −                                −                           −                                            −                                          \+                                        −                                          −                                          −                                                −                           −
  Hepatomegaly                                                                                    \+                               −                           \+                                           \+                                         \+                                        \+                                         \+                                         \+                                               \+                          \+
  Splenomegaly                                                                                    −                                −                           −                                            \+                                         \+                                        \+                                         −                                          \+                                               −                           −
  Pruritus                                                                                        \+                               \+                          \+                                           −[a](#hep29020-note-0005){ref-type="fn"}   \+                                        −[a](#hep29020-note-0005){ref-type="fn"}   −[a](#hep29020-note-0005){ref-type="fn"}   \+                                               \+                          \+
  TB                                                                                              207.9                            133.5                       133                                          158                                        205.7                                     206.7                                      117.2                                      222.9                                            39.2                        300.6
  DB                                                                                              135.9                            90.8                        47.6                                         100.5                                      137.1                                     146.5                                      58                                         120.7                                            29                          229
  ALT                                                                                             36                               40                          57                                           255                                        88                                        84                                         148                                        24                                               62                          33
  AST                                                                                             49                               41                          48                                           434                                        88                                        196                                        352                                        35                                               55                          62
  ALP                                                                                             524                              688                         NA                                           342                                        1,010                                     1,364                                      888                                        452                                              1,062                       649
  GGT                                                                                             14                               17                          42                                           47                                         10                                        99                                         85                                         13                                               10                          9
  TP                                                                                              55.4                             57                          NA                                           NA                                         50.1                                      47.1                                       68                                         NA                                               59.3                        55.2
  Alb                                                                                             27.3                             32.6                        NA                                           33.4                                       34.5                                      38.3                                       24.6                                       41                                               38                          31.6
  TBA                                                                                             NA                               366.9                       NA                                           114                                        240.9                                     180.2                                      21.2                                       222.4                                            206.2                       461.4
  Liver biopsy age                                                                                ---                              ---                         9mo                                          1mo                                        2y                                        2.5mo                                      4mo                                        ---                                              ---                         ---
  Status at most recent assessment                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Age                                                                                             7.4y                             4.4y                        2.3y                                         2.5y                                       6.9y                                      7mo                                        6.5mo                                      10.4y                                            8mo                         12mo
  Height (cm)[40](#hep29020-bib-0040){ref-type="ref"}, [41](#hep29020-bib-0041){ref-type="ref"}   106 (\<3%)                       117 (97%)                   \<80 (\<3%)                                  95 (90%)                                   106 (\<3%)                                60 (\<3%)                                  NA                                         137 (50%)                                        NA                          78 (75%)
  Weight (kg)[40](#hep29020-bib-0040){ref-type="ref"}, [41](#hep29020-bib-0041){ref-type="ref"}   16.5 (\<1%)                      19 (70%)                    9.5 (\<3%)                                   13.1 (50%)                                 16 (\<3%)                                 6 (\<3%)                                   5.5 (\<3%)                                 28 (25%)                                         NA                          10 (50%)
  TB                                                                                              32.4                             6.9                         133.5                                        9.7                                        12.4                                      118.8                                      194.9                                      237.1                                            46.8                        173.1
  DB                                                                                              13.9                             1.5                         113.9                                        1.9                                        6.2                                       82.2                                       106.4                                      124.2                                            26.6                        132.1
  ALT                                                                                             85                               42                          76                                           16                                         33                                        88                                         94                                         37                                               61                          24
  AST                                                                                             82                               39                          64                                           31                                         28                                        172                                        193                                        24                                               53                          37
  ALP                                                                                             1,721                            295                         687                                          272                                        402                                       700                                        711                                        341                                              1,489                       257
  GGT                                                                                             21                               15                          12                                           15                                         9                                         89                                         42                                         18                                               10                          19
  TP                                                                                              71                               68                          61.1                                         71                                         65.6                                      56.7                                       62.6                                       71                                               65                          60.2
  Alb                                                                                             42                               45                          35.4                                         47                                         41.8                                      42.6                                       47.2                                       43                                               41                          32.6
  TBA                                                                                             7.7                              3.9                         437.8                                        1.7                                        4.1                                       294.9                                      71.1                                       219.6                                            172.5                       209.1
  Outcome                                                                                         Mild cholestasis with pruritus   Recovered                   Listed elsewhere for LT and died aged 2.6y   Recovered with alleviated hepatomegaly     2 episodes of cholestasis with pruritus   Cholestasis                                Cholestasis                                In second episode of cholestasis with pruritus   Cholestasis with pruritus   In second episode of cholestasis with pruritus
  Characterization                                                                                Persistent cholestasis           Transient cholestasis       Persistent cholestasis                       Transient cholestasis                      Recurrent cholestasis                     Insufficient follow‐up                     Insufficient follow‐up                     Recurrent cholestasis                            Insufficient follow‐up      Recurrent cholestasis

P4, P6, and P7 were too young (\<3 months) to manifest itching‐associated behavior at first assessment.

Abbreviations and (expected ranges), biochemical tests: TB, total bilirubin (5.0‐17.1 umol/L); DB, direct bilirubin (0‐6 umol/L); ALT, alanine transaminase (0‐40 IU/L); AST, aspartate aminotransferase (0‐40 IU/L); ALP, alkaline phosphatase (42‐383 IU/L); GGT, gamma‐glutamyltransferase (7‐50 IU/L); TP, total protein (60‐83 g/L); Alb, Albumin (35‐55 g/L); TBA, total bile acids (0‐10 umol/L).

Abbreviations: mo, month(s); d, days; NA, not available; y, years.

P1 and P3 presented with persistent cholestasis. P1 received routine UDCA therapy for 1 month; his parents substituted Traditional Chinese Medicine for UDCA without any improvement. He was lost to follow‐up for around 2 years. When seen again, aged 6 years, he had mild jaundice and pruritus (TB, 85.7 umol/L; DB, 48.7 umol/L; ALT, 70 IU/L; AST, 80 IU/L). He was returned to cholestyramine and fat‐soluble vitamin therapy, with substantial improvement in symptoms (Table [2](#hep29020-tbl-0002){ref-type="table-wrap"}), but without catch‐up in growth (height, 106 cm, \<3rd percentile, August 2016).[40](#hep29020-bib-0040){ref-type="ref"}, [41](#hep29020-bib-0041){ref-type="ref"} P3 seemed nonresponsive to routine treatment, was listed for liver transplantation (LT) elsewhere at age 2.3 years, and died untransplanted 4 months later.

P5, P8, and P10 suffered from intermittent (recurrent) cholestasis. Each had two episodes of cholestasis, with pruritus during bouts, and was asymptomatic between episodes. For P5, the first episode began at age 6 months. No trigger was recognized. Treatment was given elsewhere (details not available), and cholestasis resolved after 6 months, but recurred after a fever at age 6 years. This second episode lasted for 7 months and was treated routinely with cholestyramine. With resolution of cholestasis, all biochemical test results for P5 returned to normal values. Of interest is that P5 was diagnosed with sensorineural deafness from age \<1 year and cholecystolithiasis at age 4 years. For P8, the first episode began at age 7 months. No trigger was recognized. Traditional Chinese Medicine was given; details are not available. Cholestasis resolved after 6 months and recurred, with pale stools, after taking cefixime and amoxicillin at age 10 years (March 2016), without menarche. Routine treatment was given; her parents replaced these with some folk prescription 1 month later. This bout has not resolved to date. Of interest in P8 is a history of loose stools, but not of watery diarrhea, until aged 3 years. Of interest in P10 is that both bouts of cholestasis (at 7 and 11 months) were preceded by diarrhea for 10 days that resolved before pruritus and icterus began. No trigger was recognized. Details of previous treatments elsewhere were unavailable. P10 seemed to respond to UDCA therapy in the second episode, with alleviated jaundice and normalizing clinical‐laboratory test results before discharge.

P2 and P4 had single bouts of cholestasis that resolved (transient rather than recurrent cholestasis, at least to date), without recognized triggers. P2 only received UDCA for less than 1 week, switching to methylprednisolone at his parents\' discretion. Interestingly, P2, differed from his elder brother P1, carrying the same *MYO5B* mutations, in showing normalized serum bilirubin and other liver function tests 3 weeks later (age 20 months) through to last follow‐up in January 2016 (age 4.4 years; Table [2](#hep29020-tbl-0002){ref-type="table-wrap"}). P4 had onset of cholestasis from 2 days old with hepatosplenomegaly (liver 3 cm below right costal arch and spleen 2 cm below left costal arch), but, after nearly 1 year of routine UDCA therapy with cholestyramine, he recovered with normal height and weight and mild hepatomegaly (2 cm below right costal arch; see [Supporting Fig. S2](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo) for laboratory values and management).

P6, P7, and P9 could not be classified as transient or recurrent cholestasis because of insufficient clinical follow‐up.

HISTOPATHOLOGICAL AND IMMUNOHISTOPATHOLOGICAL FINDINGS {#hep29020-sec-0012}
------------------------------------------------------

Core needle biopsy specimens of liver were available for P3, P5, P6, and P7. A wedge biopsy specimen of liver was available for P4. Liver controls from children without cholestasis were a wedge biopsy specimen obtained at choledochal cyst excision (A) and non‐neoplastic liver incidentally resected at hepatoblastoma excision (B). Wedge biopsy specimens of liver taken at hepatic portoenterostomy in extrahepatic biliary atresia served as liver controls from children with cholestasis (control A in Fig. [1](#hep29020-fig-0001){ref-type="fig"}; controls A, B, and C in Figs. [2](#hep29020-fig-0002){ref-type="fig"} and [3](#hep29020-fig-0003){ref-type="fig"}). Subsequent evaluation (B.S., A.S.K.) included material from P3, P4, and P5 as well as from a wedge biopsy specimen of liver from an infant with known *ABCB11* mutation and predicted BSEP deficiency (NM_003742: c.1243C\>T, p. I498T / c.1493T\>C, R415X, Fig. [3](#hep29020-fig-0003){ref-type="fig"}D) and discarded tissue from a healthy liver donor (Fig. [3](#hep29020-fig-0003){ref-type="fig"}E). Hepatocellular and canalicular cholestasis, with lobular disarray and giant‐cell change of hepatocytes, was observed in all patient specimens (Fig. [1](#hep29020-fig-0001){ref-type="fig"}). Marking for CK7 and CK19 highlighted slight ductular reaction in all patient specimens other than that from P6. Marking for MYO5B, in the form of fine granules, was scant in control noncholestatic liver; it was observed principally in periportal regions (Fig. [2](#hep29020-fig-0002){ref-type="fig"}, controls A and B). Granules were larger and more numerous in control cholestatic liver (Fig. [2](#hep29020-fig-0002){ref-type="fig"}C), but were similarly distributed. Coarsely granular marking for MYO5B was diffusely present in all *MYO5B* patient specimens. Marking for BSEP at bile canaliculi was initially assessed as decreased in P3‐P7, with displacement into cytoplasm in P5. Separate immunostaining with patient‐blinded review of P3‐P5 and controls A‐E (B.S., A.S.K.) found no expression of BSEP in P3 or in the patient with a known *ABCB11* mutation. In both P4 and P5, BSEP marking at bile canaliculi was assessed as weak (Fig. [3](#hep29020-fig-0003){ref-type="fig"}). ABCB4 immunostaining showed disorganized canalicular marking in MYO5B patients whereas crisply well‐defined canalicular distribution was observed in normal controls ([Supporting Fig. S3](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo)).

PLASMA BILE ACID PROFILES {#hep29020-sec-0013}
-------------------------

Plasma bile acid profiles during cholestasis in P1, P2, P4, and P5 were compared with those of 16 patients with cholestasis genetically confirmed as associated with *ABCB11* mutation and those of 20 healthy donors. A significant increase in plasma concentrations of bile acids over healthy controls was observed in the 4 *MYO5B*‐mutated patients, with much higher values for total, primary, and conjugated bile acids as well as for UDCA (Fig. [4](#hep29020-fig-0004){ref-type="fig"}). The bile acid profiles in *MYO5B* mutation were very similar to those in *ABCB11* mutation (Fig. [4](#hep29020-fig-0004){ref-type="fig"}). This suggests stagnation of hepatocellular secretion of these bile acid species into bile in both disorders. The increase of total bile acids in plasma likely resulted from both the administration of UDCA (\<200 μM) and primary cholestasis (accounting for up to 400 μM of total serum bile acids; cf. Fig. [4](#hep29020-fig-0004){ref-type="fig"}A,F). Concentrations of free bile acids in plasma were significantly lower for *MYO5B‐*mutated patients than for healthy controls (Fig. [4](#hep29020-fig-0004){ref-type="fig"}C), consistent with poor biliary secretion of bile acids and decreased concentrations of bile acids in chyme. Of note is that P2 and P4, in whom cholestasis resolved after treatment with UDCA and other medications, had higher concentrations of TBAs, secondary conjugated bile acids, and UDCA in plasma than did P1 and P5, who had persistent cholestasis (Fig. [4](#hep29020-fig-0004){ref-type="fig"}A,B,D,E,F). Bile acid profiles in plasma from P2 obtained before and after resolution of cholestasis were also compared (Table [3](#hep29020-tbl-0003){ref-type="table-wrap"}). TBA concentrations fell 100‐fold with resolution. Of interest is that whereas glycine conjugates of bile acids typically predominate in humans,[35](#hep29020-bib-0035){ref-type="ref"} taurine‐conjugated bile acid concentrations rose in P2 after resolution of cholestasis ([Supporting Table S4](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo)). The significance of these differences is unknown.

###### 

Plasma Bile Acid Profiles, Patient 2 While Jaundiced and When Recovered; Median‐Value Profiles, Plasma of Patients With ABCB11 Disease Manifest as Nonremitting Cholestasis (n = 16), of Patients With Cholestasis of Unknown Etiology (n = 19), and of Healthy Controls (n = 20)

                               Patient 2                                  
  ---------------------------- ----------- -------- ---------- ---------- --------
  Cholic acid                  0.0193      0.0485   0.0185     0.0208     0.0449
  Deoxycholic acid             0.0317      0.1130   0.0417     0.0376     0.1181
  Lithocholic acid             0.0008      0.0457   0.0013     0.0008     0.0020
  Allocholic acid              0.0044      0.0054   0.0008     0.0026     0.0072
  Chenodeoxycholic acid        0.0158      0.0747   0.0280     0.0368     0.1582
  Dehydrocholic acid           0.0021      0.0563   0.0050     0.0093     0.0093
  Ursodeoxycholic acid         0.0266      0.0389   0.1224     0.0502     0.1212
  Nordeoxycholic acid          0.0004      0.0015   0.0010     0.0008     0.0007
  λ‐Muricholic acid            0.0030      0.0295   0.0018     0.0058     0.0135
  ω‐Muricholic acid            0.0003      0.0088   0.0009     0.0007     0.0049
  Glycochenodeoxycholic acid   72.2260     0.7936   70.8114    41.8743    2.0658
  Glycocholic acid             26.5625     0.2741   30.6065    9.6260     0.4612
  Glycodeoxycholic acid        0.0674      0.0542   0.0272     0.0145     0.0624
  Glycohyodeoxycholic acid     0.0000      0.1047   0.0000     0.0000     0.0000
  Glycoursodeoxycholic acid    30.0986     0.1922   28.0995    16.9341    0.2608
  Glycolithocholic acid        0.0131      0.0032   0.0192     0.0081     0.0026
  Glycohyocholic acid          0.9492      0.0270   0.5494     0.6265     0.0429
  Taurodeoxycholic acid        0.0991      0.0231   0.0151     0.0149     0.0219
  Taurochenodexycholic acid    67.7097     0.5467   44.4753    26.4341    0.4512
  Taurocholic acid             175.9461    1.0765   34.8788    20.0363    0.1243
  Taurohyodeoxycholic acid     12.4800     0.1096   5.4691     3.3819     0.0171
  Taurolithocholic acid        0.0042      0.0011   0.0063     0.0040     0.0003
  Tauroursodeoxycholic acid    12.8510     0.1347   5.6816     3.5868     0.0168
  Taurohyocholic acid          3.9186      0.0321   1.0945     1.9210     0.0099
  Tauro‐α‐muricholic acid      0.3432      0.0212   0.1269     0.1367     0.0075
  Tauro‐β‐muricholic acid      0.0154      ND       0.0926     0.0207     0.0002
  Norcholic acid               0.0464      0.0081   0.0284     0.0364     0.0212
  Total:                       403.4351    3.8244   260.4637   194.5035   6.2923

![Bile acids in plasma of *MYO5B* mutant patients. Bile acid (BA) profiles obtained by UPLC−ESI/MRM‐MS (μM) of plasma from 4 patients carrying *MYO5B* defects, compared to those from 16 patients confirmed to harbor biallelic *ABCB11* mutations and 20 healthy controls. In the *MYO5B* group, P1, P2, and P4 refer to patients 1, 2, and 4, respectively, and (P5‐1) and (P5‐2) both refer to patient 5, sampled twice, during and after a bout of cholestasis. (A) TBAs based on 62 standards that cover all major bile acids and many rare bile acids (see [Supporting Table S4](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo)); (B) total conjugated bile acids, including glycol‐CDCA, glyco‐CA, tauro‐DCA,tauro‐CA, and tauro‐CDCA; (C) total free bile acids, including CA, CDCA, DCA and LCA; (D) total primary bile acids, including CA, CDCA, glyco‐CA, glycol‐CDCA, tauro‐CA, and tauro‐CDCA; (E) total secondary bile acids, including DCA, LCA, 7‐KLCA, 12‐KLCA, 67‐diKLCA, and DioxoLCA; (F) total UDCA including free, glycol‐, and tauro‐UDCA and their sulfated forms. The number below each of the *MYO5B* and *ABCB11* groups is the *P* value of the group versus controls.](HEP-65-1655-g004){#hep29020-fig-0004}

ISOLATED CHOLESTASIS IS MORE LIKELY ASSOCIATED WITH NONSEVERE MUTATIONS IN *MYO5B* {#hep29020-sec-0014}
----------------------------------------------------------------------------------

A review of our patients with MYO5B deficiency and those reported by others[24](#hep29020-bib-0024){ref-type="ref"}, [25](#hep29020-bib-0025){ref-type="ref"}, [27](#hep29020-bib-0027){ref-type="ref"}, [29](#hep29020-bib-0029){ref-type="ref"}, [36](#hep29020-bib-0036){ref-type="ref"}, [37](#hep29020-bib-0037){ref-type="ref"}, [38](#hep29020-bib-0038){ref-type="ref"} identified 15 patients from 13 unrelated families with isolated cholestasis and 39 patients from 38 unrelated families with MVID. We compared *MYO5B*‐associated isolated cholestasis and MVID based on nature of mutations by severity or by presumed effect on MYO5B‐RAB11A interaction. We found that biallelic severe mutations were less frequent in the isolated cholestasis subgroup than in the MVID subgroup (0 of 13 vs. 11 of 38; *P* = 0.046; Fig. [5](#hep29020-fig-0005){ref-type="fig"}) as were biallelic mutations affecting the MYO5B‐RAB11A interaction domain (5 of 13 vs. 28 of 38; *P* = 0.041).

![Schematic presentations of MYO5B protein and reported homozygous or compound heterozygous mutations. Upper arrows indicate reported mutations in MVID patients.[24](#hep29020-bib-0024){ref-type="ref"}, [25](#hep29020-bib-0025){ref-type="ref"}, [27](#hep29020-bib-0027){ref-type="ref"}, [29](#hep29020-bib-0029){ref-type="ref"}, [36](#hep29020-bib-0036){ref-type="ref"}, [37](#hep29020-bib-0037){ref-type="ref"} Lower arrows show mutations in isolated‐cholestasis patients reported in this article (thicker arrows) and elsewhere.[38](#hep29020-bib-0038){ref-type="ref"} Protein data are deduced from UniProt (<http://www.uniprot.org/uniprot/Q9ULV0>). Severe mutations include truncations and classical splicing mutations. Abbreviation: IQ, Isoleucine‐glutamine (IQ) calmodulin‐binding consensus sequence. ^\*^Mutations p.I408F and p.L528F were reported in an MVID patient with "atypical" cholestasis.[29](#hep29020-bib-0029){ref-type="ref"}](HEP-65-1655-g005){#hep29020-fig-0005}

Discussion {#hep29020-sec-0015}
==========

BIALLELIC MUTATIONS IN *MYO5B* CAUSE ISOLATED LOW‐GGT CHOLESTASIS {#hep29020-sec-0016}
-----------------------------------------------------------------

Although most cases of hereditary cholestasis in patients with low GGT levels can be explained by deficiencies in known genes ([Supporting Table S1](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo)), many remain unexplained.[10](#hep29020-bib-0010){ref-type="ref"} In this study, approximately one fifth (7 of 31) of the first two cohorts of undiagnosed low‐GGT cholestasis patients carried biallelic mutations in *MYO5B*---mutations that either had been reported as pathogenic in other patients or are predicted *in silico* to be pathogenic (Table [1](#hep29020-tbl-0001){ref-type="table-wrap"})---but not in genes known to be mutated in cholestasis ([Supporting Table S5](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo)).[33](#hep29020-bib-0033){ref-type="ref"} Histologically, we observed coarse granular marking for MYO5B (Fig. [2](#hep29020-fig-0002){ref-type="fig"}) and disruption of canalicular distribution of BSEP (Fig. [3](#hep29020-fig-0003){ref-type="fig"}; the latter can be observed in some instances of primary BSEP deficiency owing to *ABCB11* mutation). Among the 10 *MYO5B*‐mutated patients identified in this study, 2 presented with persistent cholestasis, 3 with recurrent cholestasis, and 2 with transient cholestasis, a clinical spectrum also resembling those observed in *ABCB11* mutation and in *ATP8B1* mutation.[6](#hep29020-bib-0006){ref-type="ref"}, [7](#hep29020-bib-0007){ref-type="ref"}, [8](#hep29020-bib-0008){ref-type="ref"}, [9](#hep29020-bib-0009){ref-type="ref"}

Similar plasma bile acid profiles were observed in patients with *MYO5B* mutations and in patients with *ABCB11* mutations, consistent with involvement of BSEP malfunction in the cholestasis of *MYO5B* disease (Fig. [4](#hep29020-fig-0004){ref-type="fig"}). Mutated *MYO5B* in 5 children with low‐GGT cholestasis and without MVID[38](#hep29020-bib-0038){ref-type="ref"} has been reported; however, the proportion of *MYO5B* mutation among children with genetically undiagnosed low‐GGT cholestasis was not described in that report.[38](#hep29020-bib-0038){ref-type="ref"} Our study suggests that, among Han Chinese patients, *MYO5B* defects account for a substantial proportion (∼20%) of hitherto undiagnosed hereditary low‐GGT cholestasis.

The MYO5B/RAB11A apical recycling endosome pathway is important for canalicular biogenesis, formation of the canalicular membrane, and establishment of polarity in hepatocytes through transcytosis.[23](#hep29020-bib-0023){ref-type="ref"} BSEP expression is aberrant in typical MVID patients.[31](#hep29020-bib-0031){ref-type="ref"} The abnormal expression of BSEP and the change in bile acid profiles observed in our *MYO5B*‐mutated patients suggest that *MYO5B* disease and *ABCB11* disease share impaired bile acid secretion attributed to lack of functional BSEP in the canalicular membrane.

GENOTYPE‐PHENOTYPE CORRELATION IN *MYO5B* DISEASE {#hep29020-sec-0017}
-------------------------------------------------

Frequency of biallelic severe *MYO5B* mutations and of *MYO5B* mutations predicted to affect the MYO5B‐RAB11A interaction domain differ between patients with isolated cholestasis and those with MVID. Isolated cholestasis appears to reflect relatively mild MYO5B functional deficiency, whereas severe mutations in *MYO5B* cause MVID. Cholestasis may accompany MVID; it was reported in 8 of 28 MVID patients[31](#hep29020-bib-0031){ref-type="ref"} in one study. However, most MVID patients are not noticeably cholestatic. This may be because the *MYO5B*‐associated cholestatic phenotype in MVID shows the same kind of variability that we describe in our patients. For example, it is noteworthy that our patients P3, P8, and P9 have the *MYO5B* mutations c.1021C\>T, p. Q341X[27](#hep29020-bib-0027){ref-type="ref"} and c.3046C\> T, p.R1016X reported as associated with typical early‐onset MVID,[36](#hep29020-bib-0036){ref-type="ref"} and that the severity of liver disease varies even between the brothers P1 and P2 (cf. clinical features in Results, above). Cholestatic phenotypes associated with *MYO5B* mutation thus appear to depend on modifier genes or possibly also on unknown environmental factors or epigenetic changes. In this context, the existence of a mouse model for MYO5B disease[26](#hep29020-bib-0026){ref-type="ref"} will provide a useful platform for testing mechanistic hypotheses. Such engineered mice may provide an experimental model to delineate the functional role of myosin Vb in the enterohepatic circulation of bile acids and may provide valuable clinical insights.

Among Han Chinese children, defects in *MYO5B* account for around 20% of instances of idiopathic low‐GGT intrahepatic cholestasis. Cholestasis associated with *MYO5B* mutation need not be paired with persistent watery diarrhea and may be transient, recurrent, or progressive. A lack of severe biallelic *MYO5B* mutations in *MYO5B* associated cholestasis without diarrhea suggests that cholestasis is a manifestation of relatively mild MYO5B functional deficiency.
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Additional Supporting Information may be found at [onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo](http://onlinelibrary.wiley.com/doi/10.1002/hep.29020/suppinfo).
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